Tag: Sglt 2 inhibitors

Affecting millions globally, insulin resistance is a complex metabolic issue, with an estimated 70% of people with PCOS experiencing it. While metformin has long been a foundational treatment, many people wonder *what is better than metformin for insulin resistance* when facing tolerability issues or insufficient results.

For decades, metformin has been the standard initial pharmacologic therapy for type 2 diabetes. However, recent guidelines emphasize a patient-centered approach, asking the key question: What is the first drug of choice for type 2 diabetes?, as newer drug classes may offer greater benefits for certain patients.

Despite a common misconception, prescription rates for metformin in the U.S. have more than doubled from 2004 to 2022, confirming that doctors still widely prescribe this first-line medication. The idea that physicians no longer prescribe metformin likely stems from a combination of the 2020 FDA recalls and the rise of popular newer alternatives, but it remains a staple in diabetes management for most patients.

In a significant shift in diabetes management, updated guidance from the American Diabetes Association (ADA) in late 2022 moved away from designating metformin as the universal first-line treatment for Type 2 diabetes. While the drug is still widely used, this change is a crucial reason **why do doctors no longer recommend metformin** as the automatic first choice for all patients. It signals a move toward more personalized medicine, considering newer therapies that offer expanded benefits beyond simple glycemic control.